Patrick Nolan, MD
Infectious Disease · Mobile, ALNPI 1821002205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Viiv Healthcare Company at 36.5% of the total.
Across 274 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Insmed, Inc.$1K
- Merck$610
- Gilead$252
- AbbVie$244
- Theratechnologies Inc.$242
- plus $699 from 12 others
Across 21 payments — averaging $2938.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$62K
What the payments were for
- Food & beverage$4,85394%
- Education$2866%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 94 | $1,874 |
| Insmed, Inc. | 79 | $1,217 |
| Merck | 32 | $610 |
| Gilead | 13 | $252 |
| AbbVie(2 entities) | 14 | $244 |
| Theratechnologies Inc. | 10 | $242 |
| Melinta Therapeutics, LLC | 9 | $200 |
| Paratek Pharmaceuticals, Inc. | 5 | $120 |
| Shionogi Inc | 4 | $85 |
| Tetraphase Pharmaceuticals, Inc. | 5 | $63 |
| La Jolla Pharmaceutical Company | 2 | $37 |
| Seqirus USA Inc | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Pfizer | 1 | $31 |
| Janssen Products, LP | 1 | $30 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
How this compares
$5,139 in reported general payments places this provider in the 70th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 166 | $718,790 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 22 | $345,544 |
| RukobiaFostemsavir Tromethamine | 32 | $283,094 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 62 | $263,303 |
| DovatoDolutegravir Sodium/Lamivudine | 60 | $187,374 |
| Daptomycin | 298 | $150,202 |
| AustedoDeutetrabenazine | 20 | $104,934 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 23 | $102,534 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $83,174 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 28 | $82,609 |
| JulucaDolutegravir/Rilpivirine | 16 | $55,586 |
| Vancomycin Hcl | 280 | $41,340 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $33,309 |
| ErtapenemErtapenem Sodium | 83 | $31,072 |
| Cefepime Hcl | 231 | $26,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Stribild, Genvoya, Descovy | $252 | $937,807222 claims |
| Viiv Healthcare CompanyRukobia, Triumeq, Dovato, Juluca | $1,874 | $789,357170 claims |
| Insmed, Inc.Arikayce | $1,217 | $345,54422 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Albuterol Sulfate | $32 | $106,13833 claims |
| MerckDelstrigo | $610 | $82,60928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Mobile
- Shannon TylerMobile$24K
- Dahlene FuscoMobile$21K
- Eduardo CalderonMobile$19K
- Amber BokhariMobile$7K
- John Vande WaaMobile$5K
- Edward HyndmanMobile$4K
- Steven AlsipMobile$2K
- C BodetMobile$2K
- Jenifer YehMobile$923
- Timothy IliffMobile$876
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.